A pain–killing medication (nimesulide) appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests. In laboratory experiments on breast cancer cells, scientists found that derivatives of nimesulide stopped the production of aromatase, the enzyme implicated in estrogen-dependent breast cancer. This form of breast cancer is the most common kind of breast cancer in postmenopausal women.
